{
    "id": "dbpedia_8013_0",
    "rank": 50,
    "data": {
        "url": "https://www.thetimes.com/uk/healthcare/article/pfizer-agrees-500m-deal-to-buy-british-drugmaker-v9d02n93n",
        "read_more_link": "",
        "language": "en",
        "title": "Pfizer agrees $500m deal to buy British drugmaker",
        "top_image": "https://www.thetimes.com/imageserver/image/%2Fmethode%2Ftimes%2Fprod%2Fweb%2Fbin%2F61f3703a-b6ba-11ec-8c29-375fe0cc1f19.jpg?crop=4794%2C2697%2C123%2C648&resize=1200",
        "meta_img": "https://www.thetimes.com/imageserver/image/%2Fmethode%2Ftimes%2Fprod%2Fweb%2Fbin%2F61f3703a-b6ba-11ec-8c29-375fe0cc1f19.jpg?crop=4794%2C2697%2C123%2C648&resize=1200",
        "images": [
            "https://www.thetimes.com/d/img/SundayTimesBrandMark-7e25d8dc58.webp",
            "https://www.thetimes.com/d/img/SundayTimesBrandMark-7e25d8dc58.webp",
            "https://www.thetimes.com/d/img/logos/sundaytimes-white-small-d8581d335c.png",
            "https://www.thetimes.com/imageserver/image/%2Fmethode%2Ftimes%2Fprod%2Fweb%2Fbin%2F61f3703a-b6ba-11ec-8c29-375fe0cc1f19.jpg?crop=4794%2C2697%2C123%2C648&resize=360",
            "https://www.thetimes.com/imageserver/image/%2Fmethode%2Ftimes%2Fprod%2Fweb%2Fbin%2F494c2812-b352-11ec-8ba8-f6bf3099f5f6.jpg?crop=4584%2C2579%2C0%2C239",
            "https://www.thetimes.com/imageserver/image/%2Fmethode%2Ftimes%2Fprod%2Fweb%2Fbin%2Fac06b1d0-6578-11eb-ab68-123bacbc1c7b.jpg?crop=5568%2C3132%2C0%2C290",
            "https://www.thetimes.com/d/assets/dual-masthead-bcc5303ae7.png",
            "https://www.thetimes.com/d/assets/ipso-f7843bf2cd.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Callum Jones"
        ],
        "publish_date": "2022-04-07T23:01:00+00:00",
        "summary": "",
        "meta_description": "Pfizer has agreed to buy ReViral, a privately-held business based in the UK, for as much as $525 million in a bid to gain access to experimental drugs to treat a respiratory virus.The US pharmaceutical giant said the deal was designed to strengthen its pipeline of treatments. It is its second acquis",
        "meta_lang": "en",
        "meta_favicon": "/store/favicon-32x32.png",
        "meta_site_name": "",
        "canonical_link": "https://www.thetimes.com/uk/healthcare/article/pfizer-agrees-500m-deal-to-buy-british-drugmaker-v9d02n93n",
        "text": "Pfizer has agreed to buy ReViral, a privately held business based in the UK, for as much as $525 million in an attempt to gain access to experimental drugs to treat a respiratory virus.\n\nThe US pharmaceutical giant said the deal was designed to strengthen its pipeline of treatments. It is its second acquisition in less than six months after the $6.7 billion takeover of Arena Pharmaceuticals in December.\n\nReViral, founded in 2011, is focused on discovering and developing antiviral therapeutics that target respiratory syncytial virus (RSV), which causes cold-like symptoms. It is a cause of pneumonia in young children and the elderly. It has offices in Stevenage, Hertfordshire, and in Durham, North Carolina.\n\nAlbert Bourla, chairman and chief executive of Pfizer, said: â€œWe have"
    }
}